Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
J Allergy Clin Immunol. 2021 Sep;148(3):889-894. doi: 10.1016/j.jaci.2021.02.023. Epub 2021 Mar 2.
Mastocytosis encompasses a heterogeneous group of disorders characterized by accumulation of clonal mast cells (MCs) in the skin and/or internal organs. Patients typically present with a broad variety of recurrent mediator-related clinical symptoms, including severe anaphylaxis. However, not all patients with mastocytosis experience anaphylactic reactions.
We sought to identify disease-specific biomarkers in plasma that could be used to predict patients with mastocytosis with increased risk of anaphylaxis.
Nineteen patients (≥18 years) and 2 control groups (11 subjects with allergic asthma and 13 healthy volunteers without history of atopy) were recruited. In total, 248 plasma proteins were analyzed by Proximity Extension Assay using Olink Proseek Multiplex panels.
We identified 4 novel proteins, in addition to tryptase, E-selectin, adrenomedullin, T-cell immunoglobulin, and mucin domain 1, and CUB domain-containing protein 1/CD138 to be significantly increased in patients with mastocytosis compared with both patients with asthma and healthy controls. Furthermore, we investigated whether we could discriminate between patients with mastocytosis with or without anaphylaxis. In addition to tryptase, we identified 3 novel proteins, that is, allergin-1, pregnancy-associated plasma protein-A, and galectin-3, with significantly different levels in patients with mastocytosis with anaphylaxis compared with those without anaphylaxis.
Newly identified proteomic biomarkers may be used to predict patients with mastocytosis with increased risk of anaphylaxis.
肥大细胞增多症包含一组以皮肤和/或内部器官中克隆性肥大细胞（MC）积累为特征的异质性疾病。患者通常表现出广泛的复发性介质相关临床症状，包括严重的过敏反应。然而，并非所有肥大细胞增多症患者都经历过敏反应。
我们旨在确定血浆中可用于预测肥大细胞增多症患者过敏反应风险增加的疾病特异性生物标志物。
招募了 19 名（≥18 岁）患者和 2 个对照组（11 名过敏性哮喘患者和 13 名无过敏史的健康志愿者）。总共使用 Olink Proseek Multiplex 面板通过临近延伸分析（Proximity Extension Assay）分析了 248 种血浆蛋白。
除了类胰蛋白酶、E-选择素、肾上腺髓质素、T 细胞免疫球蛋白和粘蛋白域 1 以及 CUB 结构域包含蛋白 1/CD138 外，我们还发现了 4 种新的蛋白在肥大细胞增多症患者中明显高于哮喘患者和健康对照组。此外，我们还研究了是否可以区分有无过敏反应的肥大细胞增多症患者。除了类胰蛋白酶外，我们还发现了 3 种新的蛋白，即过敏素-1、妊娠相关血浆蛋白-A 和半乳糖凝集素-3，在有过敏反应的肥大细胞增多症患者中与无过敏反应的患者相比，其水平明显不同。
新发现的蛋白质组学生物标志物可用于预测肥大细胞增多症患者过敏反应风险增加的情况。
